首页|A Chinese Multi-Specialty Delphi Consensus to Optimize RAASi Usage and Hyperkalaemia Management in Patients with Chronic Kidney Disease and Heart Failure

A Chinese Multi-Specialty Delphi Consensus to Optimize RAASi Usage and Hyperkalaemia Management in Patients with Chronic Kidney Disease and Heart Failure

扫码查看
Objective Variations are present in common clinical practices regarding best practice in managing hyperkalaemia(HK),there is therefore a need to establish a multi-specialty approach to optimal renin-angiotension-aldosterone system inhibitors(RAASi)usage and HK management in patients with chronic kidney disease(CKD)&heart failure(HF).This study aimed to establish a multi-speciality approach to the optimal use of RAASi and the management of HK in patients with CKD and HF.Methods A steering expert group of cardiology and nephrology experts across China were convened to discuss challenges to HK management through a nominal group technique.The group then created a list of 41 statements for a consensus questionnaire,which was distributed for a further survey in extended panel group of cardiologists and nephrologists across China.Consensus was assessed using a modified Delphi technique,with agreement defined as"strong"(≥75%and<90%)and"very strong"(≥90%).The steering group,data collection,and analysis were aided by an independent facilitator.Results A total of 150 responses from 21 provinces across China were recruited in the survey.Respondents were comprised of an even split(n=75,50%)between cardiologists and nephrologists.All 41 statements achieved the 75%consensus agreement threshold,of which 27 statements attained very strong consensus(≥90%agreement)and 14 attained strong consensus(agreement between 75%and 90%).Conclusion Based on the agreement levels from respondents,the steering group agreed a set of recommendations intended to improve patient outcomes in the use of RAASi therapy and HK management in China.

Sardiorenal syndromechronic kidney failureheart failurehyperkalemiamultidisciplinary communicationRAASi

Ming-Hui Zhao、Wei Chen、Hong Cheng、Bi-Cheng Liu、Zhi-Guo Mao、Zhuang Tian、Gang Xu、Jing-Min Zhou

展开 >

Renal Division,Peking University First Hospital,Beijing 100034,China

Department of Nephrology,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China

Department of Nephrology,Capital Medical University,Beijing 100029,China

Department of Nephrology,Southeast University Zhongda Hospital,Nanjing 210009,China

Department of Nephrology,Shanghai Changzheng Hospital,Shanghai 200003,China

Department of Cardiology,Peking Union Medical College Hospital,Beijing 100730,China

Renal Division,Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,China

Department of Cardiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China

展开 >

2024

中国医学科学杂志(英文版)
中国医学科学院,中国协和医科大学

中国医学科学杂志(英文版)

CSTPCD
影响因子:0.533
ISSN:1001-9294
年,卷(期):2024.39(2)